Rationale and Design:
The GLOBAL LEADERS trial was designed to challenge the current treatment paradigm consisting of 12-month dual antiplatelet therapy (DAPT; clopidogrel+aspirin among patients with stable CAD; ticagrelor+aspirin among patients with ACS) followed by aspirin monotherapy in patients undergoing PCI based on the superiority for the composite endpoint of all-cause death or Q-wave myocardial infarction (MI) assessed at 2 years. GLOBAL LEADERS Adjudication Sub-StudY (GLASSY) was designed with the aim to prospectively implement, in a representative sample of patients enrolled within the GLOBAL LEADERS trial, an independent adjudication process of reported as well as unreported potential endpoints, leveraging on standardized CEC procedures. This GLASSY substudy is powered to test whether 23-month ticagrelor monotherapy after a short course of DAPT for 1 month is non-inferior to conventional 12-month DAPT followed by aspirin monotherapy with respect to CEC-adjudicated death, non-fatal myocardial infarction, non-fatal stroke, or urgent target-vessel revascularization (TVR) and superior in preventing CEC-adjudicated major bleeding. Furthermore, GLASSY will evaluate the implications of the CEC adjudication process for the interpretation of study results by quantifying the level of concordance between IR reported and CECadjudicated events and will define the role of CEC adjudication process for the assessment of the efficacy and safety of the randomized antithrombotic strategies on a broader set of fatal and non-fatal clinical endpoints. Endpoints GLASSY will have two independent, CEC-adjudicated, co-primary endpoints at 24 months: 1) The composite of death, non-fatal MI, non-fatal stroke, or urgent TVR (coprimary efficacy endpoint);
2) The composite of BARC type 3 or 5 bleeding (co-primary safety endpoint). Secondary endpoints will include: • Each component of the co-primary composite endpoints; • Definite, probable or possible stent thrombosis according to ARC classification; • Bleeding events according to BARC, TIMI and GUSTO classifications; • Type of death (cardiovascular vs. non-cardiovascular and subtypes).
Statistical analyses
The co-primary efficacy endpoint will be firstly tested as noninferiority followed by a superiority testing only if non-inferiority criteria will be met. The co-primary safety endpoint will be tested with a superiority hypothesis only. Alpha error will be evenly split (2.5% each) between the two co-primary endpoints. A total of 3,340 patients per group (6,680 patients) will yield 85% power to detect non-inferiority with a one-sided type I error (alpha) of 2.5%. The risk ratio will be calculated using the Mantel-Cox log-rank method. 
REVISION
The topics (DAPT in patients undergoing PCI and methodological aspect related to the concordance between IR-reported and CECadjudicate events) are important topic for clinicians, researchers, patients and health policy makers, and the subject seems within the scope of BMJ Open. Furthermore, a very interesting strength of the study is its design aimed to implement CEC processes in the context of a large phase III pragmatic trial, which would let an original assessment of differences in IR-reported versus CEC-adjudicated events. Thus, the study may provide information on methodological questions exceeding the specific field (antiplatelet agents in CAD patients) and becoming of interest for research on clinical trials in general.
Research question and aims are well presented and defined. Methods are exhaustively and adequately described. In particular rationale, design end-points and data sources are clearly explained. The same for procedures and statistical analysis. Limitations are properly acknowledged .
Therefore, in my opinion, the article deserves to be accepted for publication.
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GENERAL COMMENTS
The present manuscript reports on the rationale and design of a substudy of the ongoing GLOBAL LEADERS trial. In my view this paper is not free from redundant publication.
1. Global leaders. however, all but one of the authors (Canada) are from Europe. this initiative clearly does not represent a global perspective. please comment. 2. Global leaders is a superiority trial. GLASSY is started as a noninferior study. Why this discrepancy ? 3. Bleeding endpoints are scored by different criteria, but this is not uniformly reported thorughout the doucment and ranges from BARC only to all three most common criteria sets available in literature such as GUSTO and TIMI. please adjust. 4. endpoints: page 4. GLASSY on several non-fatal endpoints. however, death is part of the primary endpoint in GL study. Please comment and adjust. 5. my main issue is that GLOBAL leaders is designed as an investigator reported only study. GLASSY is now there to adjudicate in about half the patients on the reliability of the GL design. this seems very ineffective, also as investigators will know that CEC adjudicated analysis will follow their IR data. GLASSY in my view may cause bias for GLdesign. 6. If the authjors still wish to perform GLASSY, they may mention this as an amendment online to the Original trial protocol instead. it remains unclear to me why this GLASSY protocol should be published as a separate study protocol as it contains overlap with the GL protocol in approx 80% of the document. 7. "Independency of parent study". Why is this truly independent, and if so, why do the authors believe that this is relevant ? 8. Evaluation of endpoints. "Concordance between IR and CEC adjudicated endpoints will be assessed in events with sufficient evidence only". this seems a very weak point in the design, while you may miss many endpoints. Please comment.
REVIEWER
Bhiken Naik University of Virginia USA REVIEW RETURNED 29-Oct-2018
GENERAL COMMENTS
The study is well designed and I recommend acceptance of this manuscript
VERSION 1 -AUTHOR RESPONSE
Reviewer 2 The topics (DAPT in patients undergoing PCI and methodological aspect related to the concordance between IR-reported and CEC -adjudicate events) are important topic for clinicians, researchers, patients and health policy makers, and the subject seems within the scope of BMJ Open. Furthermore, a very interesting strength of the study is its design aimed to implement CEC processes in the context of a large phase III pragmatic trial, which would let an original assessment of differences in IR-reported versus CEC-adjudicated events. Thus, the study may provide information on methodological questions exceeding the specific field (antiplatelet agents in CAD patients) and becoming of interest for research on clinical trials in general.
Research question and aims are well presented and defined. Methods are exhaustively and adequately described. In particular rationale, design end-points and data sources are clearly explained. The same for procedures and statistical analysis. Limitations are properly acknowledged. Therefore, in my opinion, the article deserves to be accepted for publication.
